secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001628280-25-011839
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics Q4/FY2024 net loss $26.4M; cash into H2 2026; OV329 data Q3 2025
--------------------------------------------------------------------------------

- Net loss $26.4M ($0.37/diluted) for FY2024 vs $52.3M in 2023; royalty revenue $566K.
- Cash & securities $53.1M expected to fund operations into H2 2026.
- Topline Phase 1 results for OV329 (GABA-AT inhibitor) expected Q3 2025; no SAEs to date.
- OV350 (first KCC2 direct activator) began Phase 1 in Q1 2025; topline data expected Q4 2025.
- Stelios Papadopoulos appointed to Board; Manal Morsy (Chief Regulatory Officer) and Victoria Fort (Corporate Affairs) joined.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/0001628280-25-011839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/ovid-20250311.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-011839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer